Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Alcohol Consumption and Health Effects, and Drug-Induced Hepatotoxicity and Protection.
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis
Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease
Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study
MyWayUp: A Digital Intervention for Alcohol Use Disorder in Patients With Alcohol-Related Liver Disease-Results From an RCT.
Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis.
Urine Proteomics in Cirrhosis and Acute Kidney Injury: Insights Into the Pathogenesis of Hepatorenal Syndrome.
LiverRisk score (LRS) predicts long-term liver-related outcomes in a cohort of Veterans without evidence of liver disease.
Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease.
Simvastatin and Rifaximin in Decompensated Cirrhosis
Alcohol-associated liver disease: Natural history, management and novel targeted therapies.
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
MetALD: Clinical aspects, pathophysiology and treatment.
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Moving diagnosis of liver fibrosis into the community
[Liver Cirrhosis: ancient disease, new challenge].
The People-First Liver Charter
Moving diagnosis of liver fibrosis into the community.
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damage.
Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus
Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus.
Diagnosis and Management of Early Stages of ALD.
Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter.
Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd).
Liver Health: An Emerging Concept.
Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd).
Simvastatin and Rifaximin for Patients With Decompensated Cirrhosis-Reply.